Trusted Resource for Clinical Trials, Protocols & Progress
Use of Digital Health Technologies in Phase 3 Clinical Trials: Tools, Benefits, and Regulatory Alignment How Digital Health Technologies Are Transforming Phase 3 Clinical Trials Why Digital Innovation Matters in Phase 3 Trials Phase 3 clinical trials represent the final step before regulatory submission, involving thousands of patients, global sites, and high stakes. Traditional models…
Sample Size Calculation for Parallel Group Studies – Clinical Trial Design and Protocol Development “Calculating Sample Size for Parallel Group Research” Introduction to Sample Size Calculation for Parallel Group Studies Sample size calculation is a critical step in the planning of clinical trials, including parallel group studies. The sample size has a significant impact on…
Lifecycle Drug Management: From Approval to Sunset via Phase 4 Clinical Trials How Phase 4 Studies Shape the Full Lifecycle of a Drug: From Market Launch to Withdrawal Introduction: Drug Lifecycle Management Beyond Approval Most people associate clinical research with drug development and approval. But a drug’s journey doesn’t end with regulatory clearance—it merely enters…
Read More “Lifecycle Drug Management: From Approval to Sunset via Phase 4 Clinical Trials” »
Oncology-Specific Phase 2 Design Strategies Strategic Design Approaches for Oncology Phase 2 Clinical Trials Introduction Oncology clinical trials are often at the forefront of innovation in trial design due to the urgent need for effective treatments and the complex biology of cancer. Phase 2 oncology trials serve as a critical step in evaluating efficacy signals,…
Stratification Techniques in Parallel Trials – Clinical Trial Design and Protocol Development “Methods of Stratification in Concurrent Trials” Introduction Stratification techniques in parallel trials are an essential part of clinical research. In the pharmaceutical industry, these techniques are used to minimize potential bias and to ensure that the results obtained are reliable and reproducible. This…
Planning for Drug-Device Combination Studies in Early Phase Trials Designing Effective Phase 1 Trials for Drug-Device Combination Products Introduction The intersection of drugs and medical devices in a single product—known as a drug-device combination (DDC)—is transforming how therapies are delivered across areas like diabetes, asthma, oncology, and pain management. In early development, these products require…
Read More “Planning for Drug-Device Combination Studies in Early Phase Trials” »
Patient Diversity and Inclusion in Global Phase 3 Trials: Strategies, Regulations, and Real-World Impact How to Ensure Patient Diversity and Inclusion in Global Phase 3 Clinical Trials Why Diversity Matters in Phase 3 Trials Phase 3 trials aim to confirm the safety and efficacy of investigational drugs across a broad population. Yet, without adequate patient…
Managing Baseline Imbalance in Parallel Designs – Clinical Trial Design and Protocol Development “Handling Unequal Baselines in Parallel Design Structures” Introduction In clinical studies, a parallel design is a research method where two or more groups of subjects are treated simultaneously. Any discrepancies between these groups at baseline (before treatment is administered) can lead to…
Cell and Gene Therapy Challenges in Phase 2 Navigating Phase 2 Challenges in Cell and Gene Therapy Trials Introduction Cell and gene therapies represent the frontier of modern medicine, offering potentially curative treatments for genetic disorders, cancers, and rare diseases. However, Phase 2 trials for these therapies introduce unique scientific, operational, manufacturing, and regulatory challenges….
Phase 4 Trials in Nutraceuticals and Over-the-Counter (OTC) Products: Post-Marketing Strategies for Safety and Evidence Generation Exploring the Role of Phase 4 Studies in Nutraceuticals and OTC Medicines Introduction: The Overlooked Frontier of Post-Marketing Surveillance Unlike prescription drugs, nutraceuticals and OTC products often reach consumers without the stringent pre-approval clinical testing required for pharmaceuticals. However,…
